Opus Genetics Updates on Gene Therapy Developments
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3 days ago
0mins
Source: NASDAQ.COM
- Gene Therapy Progress: Opus Genetics provided updates on various gene therapies for inherited retinal diseases at the R&D Science Forum, with OPGx-RDH12 set to begin clinical testing in Q4 this year, targeting approximately 30,900 patients with LCA, indicating significant therapeutic potential.
- Clinical Trial Plans: OPGx-MERTX, aimed at MERTK mutations causing severe vision loss, is expected to enter clinical testing in 2027, focusing on restoring retinal pigment epithelium metabolism, which suggests future treatment possibilities.
- Vision Improvement Results: In the Phase 1/2 trial of OPGx-LCA5, significant vision improvements were observed in both adult and pediatric patients after 24 and 6 months respectively, demonstrating the therapy's effectiveness and durability.
- Upcoming Trials: The company has initiated recruitment for the Phase 3 trial of OPGx-LCA5, with dosing expected to start in Q4 this year, while topline data from the Phase 1/2 trial for OPGx-BEST1 is anticipated in September 2026, further advancing the R&D pipeline.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IRD?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IRD
Wall Street analysts forecast IRD stock price to rise
9 Analyst Rating
9 Buy
0 Hold
0 Sell
Strong Buy
Current: 4.060
Low
6.00
Averages
8.00
High
9.00
Current: 4.060
Low
6.00
Averages
8.00
High
9.00
About IRD
Opus Genetics, Inc. is a clinical-stage ophthalmic biotechnology company. The Company is engaged in developing gene therapies for the treatment of inherited retinal diseases (IRDs) and other types of therapies for additional ophthalmic disorders. The Company’s pipeline includes adeno-associated virus (AAV)-based investigational gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA) and retinitis pigmentosa. Its pipeline also includes OPGx-BEST1 investigational gene therapy, designed to address mutations in the BEST1 gene, which is associated with retinal degeneration. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist being investigated to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 being investigated to slow the progression of non-proliferative diabetic retinopathy.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Opus Genetics Updates on Gene Therapy Developments
- Gene Therapy Progress: Opus Genetics provided updates on various gene therapies for inherited retinal diseases at the R&D Science Forum, with OPGx-RDH12 set to begin clinical testing in Q4 this year, targeting approximately 30,900 patients with LCA, indicating significant therapeutic potential.
- Clinical Trial Plans: OPGx-MERTX, aimed at MERTK mutations causing severe vision loss, is expected to enter clinical testing in 2027, focusing on restoring retinal pigment epithelium metabolism, which suggests future treatment possibilities.
- Vision Improvement Results: In the Phase 1/2 trial of OPGx-LCA5, significant vision improvements were observed in both adult and pediatric patients after 24 and 6 months respectively, demonstrating the therapy's effectiveness and durability.
- Upcoming Trials: The company has initiated recruitment for the Phase 3 trial of OPGx-LCA5, with dosing expected to start in Q4 this year, while topline data from the Phase 1/2 trial for OPGx-BEST1 is anticipated in September 2026, further advancing the R&D pipeline.
See More
Wall Street's Latest Ratings and Price Target Adjustments
- Broadcom Rating Adjustment: Morgan Stanley raised Broadcom's price target from $485 to $502, reflecting strong performance amid high expectations, indicating a sustained growth trend that may attract more investor interest.
- RTX Upgraded to Buy: Jefferies upgraded RTX from hold to buy, emphasizing its leading position in aerospace and defense, with significant growth potential from market expansion and budget support, enhancing investor confidence.
- FedEx Freight Coverage Initiated: Wolfe initiated coverage on FedEx Freight with an Outperform rating, expecting material EPS growth in the coming years driven by company-specific pricing and margin opportunities, indicating a positive market outlook.
- Alphabet Maintained Buy Rating: Bank of America reiterated its buy rating on Alphabet, anticipating 2027 capex of $241 billion and $16 billion in free cash flow, showcasing strong performance in future market demand.
See More
Opus Genetics Reports Q1 Losses and Revenue Decline
- Earnings Miss: Opus Genetics reported a Q1 GAAP EPS of -$0.75, missing expectations by $0.60, indicating significant challenges in profitability that could undermine investor confidence.
- Revenue Decline: The company’s Q1 revenue of $2.16M represents a 50.6% year-over-year decline, falling short of expectations by $0.77M, reflecting weak market demand and poor product sales, which may lead to tighter cash flow in the future.
- Financing Support: Opus Genetics secured up to $155M in financing from Oberland Capital, providing essential operational funds that will help the company maintain R&D and market expansion efforts amid adversity.
- Historical Performance Review: Despite the poor Q1 results, historical earnings data suggests that the company has asymmetric upside potential with its LCA5 and BEST1 projects, indicating possible future business recovery.
See More
Opus Genetics Reports Vision Restoration Data in Pediatric Patients
- Clinical Data Breakthrough: Opus Genetics presented six-month clinical data at the ARVO Annual Meeting indicating that LCA5 gene therapy successfully restores cone-mediated vision in pediatric patients, with sensitivity improvements exceeding 30-fold, highlighting the treatment's efficacy and potential market demand.
- Vision Function Improvement: Following a single subretinal injection, patients demonstrated early and durable improvements in functional vision tests, suggesting that even in severe early-onset diseases, there remains an opportunity for vision restoration, potentially laying the groundwork for future treatment options.
- Multiple Research Advancements: Preliminary results indicate that BEST1 gene therapy also achieved improvements in visual acuity in adult patients with no significant adverse reactions, supporting Opus Genetics' broader rollout of its gene therapy products across a larger population.
- Technological Innovation and Scalability: The company's developed cell-based expression and functional potency assays demonstrated consistent efficacy, supporting its capabilities in regulatory readiness and scalable production, further enhancing its competitive edge in the gene therapy sector.
See More
Opus Genetics Receives FDA RDEP Designation for LCA5 Gene Therapy
- FDA RDEP Designation: Opus Genetics announced that its OPGx-LCA5 gene therapy program has received the Rare Disease Evidence Principle (RDEP) designation from the FDA, marking a significant advancement in the treatment of LCA5 retinal disease and expected to expedite clinical development.
- Disease Context: LCA5 is a rare inherited retinal disease caused by biallelic mutations in the LCA5 gene, leading to severe visual impairment in childhood, with no FDA-approved therapies currently available, highlighting the market potential for this treatment.
- Therapeutic Mechanism: The OPGx-LCA5 gene therapy delivers a functional LCA5 gene to the outer retina using an adeno-associated viral vector and has previously received FDA designations as a rare pediatric disease, orphan drug, and regenerative medicine advanced therapy (RMAT), indicating its innovative nature in the treatment landscape.
- Clinical Trial Progress: The company is currently evaluating OPGx-LCA5 in an ongoing Phase 1/2 trial and plans to align with the FDA on the pivotal Phase 3 program, which is expected to provide new treatment options for patients and drive future growth for the company.
See More
Opus Genetics' OPGx-LCA5 Accepted into FDA's Rare Disease Program
- FDA Program Participation: Opus Genetics' OPGx-LCA5 gene therapy has been accepted into the FDA's Rare Disease Evidence Principles (RDEP) program, marking a significant regulatory support milestone that is expected to expedite clinical trial design and approval processes for treatments targeting LCA5.
- Clinical Trial Progress: Currently undergoing a Phase 1/2 clinical trial at the University of Pennsylvania, OPGx-LCA5 has shown promising results with pediatric participants demonstrating significant vision improvements and good tolerability, with no serious adverse events reported, indicating the therapy's potential efficacy.
- Strategic Importance: By obtaining RDEP eligibility, Opus Genetics can engage in early and ongoing collaboration with the FDA, which not only aids in optimizing its pivotal Phase 3 program but also potentially provides faster treatment options for patients, addressing the urgent market demand for effective therapies.
- Multiple Designations: OPGx-LCA5 has also received FDA designations as a Rare Pediatric Disease, Orphan Drug, and Regenerative Medicine Advanced Therapy (RMAT), further enhancing its competitive position in the market and paving the way for future commercialization.
See More
Opus Genetics Updates on Gene Therapy Developments
- Gene Therapy Progress: Opus Genetics provided updates on various gene therapies for inherited retinal diseases at the R&D Science Forum, with OPGx-RDH12 set to begin clinical testing in Q4 this year, targeting approximately 30,900 patients with LCA, indicating significant therapeutic potential.
- Clinical Trial Plans: OPGx-MERTX, aimed at MERTK mutations causing severe vision loss, is expected to enter clinical testing in 2027, focusing on restoring retinal pigment epithelium metabolism, which suggests future treatment possibilities.
- Vision Improvement Results: In the Phase 1/2 trial of OPGx-LCA5, significant vision improvements were observed in both adult and pediatric patients after 24 and 6 months respectively, demonstrating the therapy's effectiveness and durability.
- Upcoming Trials: The company has initiated recruitment for the Phase 3 trial of OPGx-LCA5, with dosing expected to start in Q4 this year, while topline data from the Phase 1/2 trial for OPGx-BEST1 is anticipated in September 2026, further advancing the R&D pipeline.
See More
Wall Street's Latest Ratings and Price Target Adjustments
- Broadcom Rating Adjustment: Morgan Stanley raised Broadcom's price target from $485 to $502, reflecting strong performance amid high expectations, indicating a sustained growth trend that may attract more investor interest.
- RTX Upgraded to Buy: Jefferies upgraded RTX from hold to buy, emphasizing its leading position in aerospace and defense, with significant growth potential from market expansion and budget support, enhancing investor confidence.
- FedEx Freight Coverage Initiated: Wolfe initiated coverage on FedEx Freight with an Outperform rating, expecting material EPS growth in the coming years driven by company-specific pricing and margin opportunities, indicating a positive market outlook.
- Alphabet Maintained Buy Rating: Bank of America reiterated its buy rating on Alphabet, anticipating 2027 capex of $241 billion and $16 billion in free cash flow, showcasing strong performance in future market demand.
See More
Opus Genetics Reports Q1 Losses and Revenue Decline
- Earnings Miss: Opus Genetics reported a Q1 GAAP EPS of -$0.75, missing expectations by $0.60, indicating significant challenges in profitability that could undermine investor confidence.
- Revenue Decline: The company’s Q1 revenue of $2.16M represents a 50.6% year-over-year decline, falling short of expectations by $0.77M, reflecting weak market demand and poor product sales, which may lead to tighter cash flow in the future.
- Financing Support: Opus Genetics secured up to $155M in financing from Oberland Capital, providing essential operational funds that will help the company maintain R&D and market expansion efforts amid adversity.
- Historical Performance Review: Despite the poor Q1 results, historical earnings data suggests that the company has asymmetric upside potential with its LCA5 and BEST1 projects, indicating possible future business recovery.
See More
Opus Genetics Reports Vision Restoration Data in Pediatric Patients
- Clinical Data Breakthrough: Opus Genetics presented six-month clinical data at the ARVO Annual Meeting indicating that LCA5 gene therapy successfully restores cone-mediated vision in pediatric patients, with sensitivity improvements exceeding 30-fold, highlighting the treatment's efficacy and potential market demand.
- Vision Function Improvement: Following a single subretinal injection, patients demonstrated early and durable improvements in functional vision tests, suggesting that even in severe early-onset diseases, there remains an opportunity for vision restoration, potentially laying the groundwork for future treatment options.
- Multiple Research Advancements: Preliminary results indicate that BEST1 gene therapy also achieved improvements in visual acuity in adult patients with no significant adverse reactions, supporting Opus Genetics' broader rollout of its gene therapy products across a larger population.
- Technological Innovation and Scalability: The company's developed cell-based expression and functional potency assays demonstrated consistent efficacy, supporting its capabilities in regulatory readiness and scalable production, further enhancing its competitive edge in the gene therapy sector.
See More
Opus Genetics Receives FDA RDEP Designation for LCA5 Gene Therapy
- FDA RDEP Designation: Opus Genetics announced that its OPGx-LCA5 gene therapy program has received the Rare Disease Evidence Principle (RDEP) designation from the FDA, marking a significant advancement in the treatment of LCA5 retinal disease and expected to expedite clinical development.
- Disease Context: LCA5 is a rare inherited retinal disease caused by biallelic mutations in the LCA5 gene, leading to severe visual impairment in childhood, with no FDA-approved therapies currently available, highlighting the market potential for this treatment.
- Therapeutic Mechanism: The OPGx-LCA5 gene therapy delivers a functional LCA5 gene to the outer retina using an adeno-associated viral vector and has previously received FDA designations as a rare pediatric disease, orphan drug, and regenerative medicine advanced therapy (RMAT), indicating its innovative nature in the treatment landscape.
- Clinical Trial Progress: The company is currently evaluating OPGx-LCA5 in an ongoing Phase 1/2 trial and plans to align with the FDA on the pivotal Phase 3 program, which is expected to provide new treatment options for patients and drive future growth for the company.
See More
Opus Genetics' OPGx-LCA5 Accepted into FDA's Rare Disease Program
- FDA Program Participation: Opus Genetics' OPGx-LCA5 gene therapy has been accepted into the FDA's Rare Disease Evidence Principles (RDEP) program, marking a significant regulatory support milestone that is expected to expedite clinical trial design and approval processes for treatments targeting LCA5.
- Clinical Trial Progress: Currently undergoing a Phase 1/2 clinical trial at the University of Pennsylvania, OPGx-LCA5 has shown promising results with pediatric participants demonstrating significant vision improvements and good tolerability, with no serious adverse events reported, indicating the therapy's potential efficacy.
- Strategic Importance: By obtaining RDEP eligibility, Opus Genetics can engage in early and ongoing collaboration with the FDA, which not only aids in optimizing its pivotal Phase 3 program but also potentially provides faster treatment options for patients, addressing the urgent market demand for effective therapies.
- Multiple Designations: OPGx-LCA5 has also received FDA designations as a Rare Pediatric Disease, Orphan Drug, and Regenerative Medicine Advanced Therapy (RMAT), further enhancing its competitive position in the market and paving the way for future commercialization.
See More
